Sign up now and fund within 24h to get free NKE, GPRO or DBX stock. T&Cs apply.
Redeem Now

ProKidney Corp

1 day chart

Kickstart your portfolio with a U.S. stock on us

Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.

Sign up and fund a new Wall St account and get a full U.S. share.

T&Cs apply
Claim now
Kickstart your portfolio with a U.S. stock on us

About PROK

ProKidney Corp. is a clinical-stage cellular therapeutics company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, rilparencel, is designed to preserve kidney function in a CKD patient’s diseased kidneys. Rilparencel is a product that includes autologous selected renal cells (SRCs) prepared from a patient’s own (autologous) kidney cells. Rilparencel is an investigational product that includes a mixture of kidney cells prepared from the participant’s own kidney tissue. The SRC are formulated rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure that is repeatable, if necessary. It is conducting a global Phase III development program and multiple Phase II clinical trials for rilparencel in subjects with moderate to severe CKD and diabetes.

Find out what a historical investment in ProKidney Corp would be worth today using our PROK stock calculator.

Market Capitalisation

$232.23M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

583.22K

High today

$0.81

Low today

$0.75

Open price

$0.80

52-week high

$4.35

52-week low

$0.46

Ready to start your investing journey with Stake?

Open an account

PROK FAQs

Buying PROK shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in ProKidney Corp in minutes.
  1. Sign up with some I.D. and zero paperwork
  2. Add funds to your account
  3. Make your first investment in PROK

The ticker symbol for ProKidney Corp is PROK.

One share of PROK is valued at $0.77 as of 22 May 2025.

As of 22 May 2025 ProKidney Corp has a market cap of $232.23M.

The ProKidney Corp 52-week high stock price is $4.35.

The ProKidney Corp 52-week low stock price is $0.46.

Yes, the Stake investing platform allows you to buy PROK shares and over 12,000 more stocks and ETFs across the ASX and Wall St.

This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in PROK
on Stake

Buy PROK from US$3 brokerage

Invest in 9,500+ U.S. stocks and ETFs

Own a slice of PROK from only US$10 with fractional shares

Get started
Stake app chart
Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.
PROK related stocks

Stake logo
Over 12,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd, trading as Stake, ACN 610 105 505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd ACN 648 283 532 (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The Stake Accumulate Fund (ARSN 680 653 374) is issued by K2 Asset Management Ltd (ABN 95 085 445 094 AFSL 244 393), a wholly owned subsidiary of K2 Asset Management Holdings Ltd (ABN 59 124 636 782). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2025 Stake. All rights reserved.